SCHEMBL3564848

SCHEMBL3564848

CC(C)(C)NS(=O)(=O)c1cccc(-c2cn(-c3nc(-c4ccc(F)c(F)c4)cc(C(F)(F)F)n3)cn2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
SDHB P21912 2/20 0.37
CYP2D6 P10635 1/20 0.37
KDM4E B2RXH2 4/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 2/20 0.36
HSP90AA1 P07900 1/20 0.36
ALOX5AP P20292 3/20 0.36
FEN1 P39748 2/20 0.36
TDP1 Q9NUW8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563604 0.92 KDM4E (0.43) JAK2ALDH1A1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3561032 0.91 MAPT (0.42) JAK2ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3562723 0.90 KIF18A (0.41) JAK2ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3561188 0.90 ALDH1A1 (0.42) JAK2ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3565406 0.89 HPGD (0.39) JAK2ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3559836 0.88 SDHB (0.38) JAK2ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3563320 0.86 PTGS2 (0.45) ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2C19
SCHEMBL3561001 0.84 ALOX5AP (0.37) ALDH1A1SMN1; SMN2KDM4EKMT2AMAPT
SCHEMBL2402187 0.83 ALDH1A1 (0.36) JAK2ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3567067 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 JAK2 1623/4885ALDH1A1 1138/4885HPGD 1536/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 JAK2 439/4885ALDH1A1 3286/4885HPGD 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.